Qure's valuation appears slightly high relative to peers, with limited upside potential. Click here to learn why QURE stock ...

Gene-editing therapies—techniques that modify DNA to treat or prevent disease—have the potential to transform the field of ...

The increasing complexity of emerging therapies and the need for faster development have led to the adoption of advanced ...

After 44 days, Kendric Cromer, 12, left the hospital. While his family feels fortunate that he was the first to receive a ...

As Shift Bioscience raises $16 million in seed funding, delve into the field of cellular reprogramming to tackle age-related ...

Confounding data from a Pfizer clinical trial have rattled the field of gene therapy for Duchenne muscular dystrophy ...

The first patient has been dosed in an open-label Phase 1/2 clinical trial of AMT-162, uniQure's one-time gene therapy for ...

Discovered 30 years ago, microRNAs are increasingly recognized as important regulators of cell physiology and human disease.

(Reuters) - Catalent CEO Alessandro Maselli said on Monday he will remain at the helm of the U.S.-based contract drugmaker ...

A Phase 3 clinical trial investigating Elevidys (delandistrogene moxeparvovec), a gene therapy for Duchenne muscular ...

On 4 November, Knut Steffensen will be taking up office as the director of the Karolinska ATMP Centre, a leading centre for advanced therapy medicinal products, with research, manufacture and ...

In the wake of Pfizer’s voluntary market withdrawal of the popular sickle cell disease therapy, BioSpace looks at five investigational drugs currently making their way through the pipeline.